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mDITORIAL COMMENT
id We Enjoy the Debate
ut Forget the Patient?
amir R. Kapadia, MD, FACC,†
avid J. Moliterno, MD, FACC‡
leveland, Ohio; and Lexington, Kentucky
he number of percutaneous coronary revascularization
rocedures performed has skyrocketed in recent years. The
ationale for this acceleration has been the rapid and
ustained relief of angina with percutaneous coronary revas-
ularization and its ease of delivery relative to surgery.
lthough it is clear that for the majority of patients
ercutaneous and surgical revascularization therapies serve
ainly as a symptomatic treatment, physicians and patients,
onsciously or subconsciously, tend to give lesser value to
otentially more important disease-modifying therapies. In
atients with coronary artery disease (CAD), these disease-
odifying treatments include pharmacologic interventions
uch as lipid-lowering agents, antiplatelet medications,
ngiotensin-converting enzyme inhibitors, beta-blockers,
nd lifestyle changes, such as smoking cessation, weight
eduction, regular exercise, stress reduction, and so on.
See page 766
everal randomized trials have compared percutaneous ver-
us surgical revascularization for symptom relief and need
or repeat revascularization as well as for reduction of death
nd myocardial infarction rates (1). Besides comparing
evascularization strategies, these trials have shed light on
he mechanisms of success and failure of each therapy. In
his issue of the Journal, Alderman et al. (2) report data from
five-year angiographic follow-up of a subgroup of patients
n the Bypass Angioplasty Revascularization Investigation
BARI) trial and implicate native disease progression as the
eading mechanism of angina recurrence. This study, using
etailed angiographic analysis, underscores the importance
f disease-modifying treatments to complement revascular-
zation procedures.
In the BARI trial, 1,829 patients with multivessel coro-
ary artery disease were randomly assigned between 1988
nd 1991 to balloon percutaneous transluminal coronary
ngioplasty (PTCA) or coronary artery bypass graft surgery
CABG). The five-year survival rate was similar for patients
ssigned to PTCA or CABG (86.3% vs. 89.3%, respec-
ively; p 0.19) (3). Systematic angiographic follow-up was
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Cardiovascular Medicine, Cleveland Clinic Foundation,
leveland, Ohio; and the ‡Gill Heart Institute and Division of Cardiovascularfedicine, University of Kentucky, Lexington, Kentucky.erformed in 5 of 18 centers and was completed in 79% of
orresponding patients (n  407). From this substudy, the
uthors report that the “culprit” for recurrence of angina five
ears after revascularization is predominantly the progres-
ion of native CAD and not necessarily the failure of the
riginal revascularization procedure. There are several other
oteworthy details in this important angiographic analysis.
The investigators in the BARI study used an angio-
raphic score, a so-called myocardial jeopardy index (MJI),
o measure the extent of CAD. The MJI was calculated
rom an anatomic representation of the size and distribution
f those coronary arteries with 50% diameter stenosis.
he BARI jeopardy score is notably different from other
imilarly intended scores, such as the Duke Jeopardy Score
nd the Alberta Provincial Project for Outcome Assessment
n Coronary Heart Disease Lesion Score (4). Unlike these
ther scores, the BARI MJI uses a cut point of 50%
iameter stenosis (rather than 70%), and it takes into
ccount the size and length of the artery. This definition
akes the MJI index potentially more representative of
iffuse, moderate atherosclerotic disease. It may make this
ndex less objective, although in the current study the
uthors reported high reproducibility. The one-year angio-
raphic analysis from this same study group reported an
dds ratio of 1.28 per 10% increase in MJI to predict angina,
hich is similar to that (1.22) reported in the present study
5). Although MJI has been shown to correlate with angina,
here are several limitations of this methodology. This index
oes not take into account the presence of collateral circu-
ation or myocardial scar (50% of the study population had
previous myocardial infarction). Even more relevant to the
resent study, this index does not take into account the type
f vessel with stenosis. A 50% stenosis in a native vessel
ikely has different prognostic implication as compared with
50% stenosis in a saphenous vein graft or a 50% restenotic
esion. Some studies have found the MJI of the BARI study
o predict future adverse cardiac events (4), but the signif-
cance of this index is less certain for patients with previous
r subsequent CABG.
In the current study, Alderman et al. (2) report MJI five
ears after randomization irrespective of intercurrent revas-
ularization procedures. Repeat revascularization was per-
ormed in 53% of patients who were initially treated with
alloon PTCA and 8% of the patients who were initially
reated with CABG. As long as the repeat revascularization
rocedure was successful, the supplied area of myocardium
t five years was considered to be “not jeopardized.” In other
ords, this analysis included primary and secondary revas-
ularization procedures at five years. It is well established
hat if restenosis does occur after balloon PTCA, it does so
ithin the first year after the procedure, not later. Similarly,
ABG compromise (beyond immediate graft failure) is
oughly 10% in the first five years. With these caveats in
ind, it is not particularly surprising that the leading causeor jeopardized myocardium during this study interval was
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Editorial Comment August 18, 2004:775–7he progression of native disease and not intermediate-term
evascularization failure (35% vs. 21%).
This substudy highlights another interesting finding that
an be interpreted in different ways. The authors note that
t the time the BARI study was conducted, the “residual
JI” after balloon PTCA was higher than that after CABG
17% vs. 7%). On the other hand, the index PTCA was
uccessful without recurrence of stenosis at five years in 61%
f lesions, and 23% of recurrent lesions were successfully
etreated. This resulted in only an 8% increase in the MJI in
he PTCA group during the five years. Conversely, at late
ollow-up in the CABG group, 16% of vein grafts had
50% stenosis, and an additional 13% were totally oc-
luded. This, combined with the compromise of 16% of left
nternal mammary artery grafts, resulted in a 13% increase
n the MJI in the CABG group during the same time
eriod. Therefore, although the MJI at five years was higher
n the PTCA group compared with CABG group (25% vs.
0%), an impressive catch-up was observed for the CABG
roup.
Many factors could have contributed to this catch-up or
urgical late-loss phenomenon. That revascularization fail-
re was comparable between PTCA- and CABG-assigned
atients (20% vs. 22%) at five-year follow-up is concerning
or CABG because this usually marks the beginning of a
igher attrition rate for vein graft conduits. Overall, disease
rogression in native vessels was more pronounced in
atients treated with CABG. Disease progression was
imilar between the groups in untreated vessels (79% vs.
3%) but was more frequent in the CABG group for treated
essels (34% vs. 45%). It is possible that surgical manipu-
ation somewhat contributed to lesion progression (e.g.,
robing the recipient vessel distal to graft anastomosis).
everal studies have noted that lesions that are bypassed
rogress or narrow faster than the non-bypassed lesions (6),
ut the differences between revascularization strategies re-
arding native disease progression have not been well
haracterized. More importantly, whether this faster pro-
ression of atherosclerosis is clinically important is not
nown. The present study might suggest that the initial
trategy of CABG results in worse progression of disease
hat leads to greater change in MJI as early as five years after
he procedure.
In current practice, whether one form of revascularization
s particularly better than the other is not possible to
pecifically answer from this analysis and, for that matter,
rom the original BARI study itself. The mechanics of
TCA and CABG have both changed significantly since
he BARI study. Greater evolution has occurred in percu-
aneous revascularization, where a multiple-fold reduction
n restenosis (from 1 in 3 to 1 in 20 patients) has taken place
ith drug-eluting stents (7). Furthermore, the procedural
isk associated with percutaneous revascularization has sub-
tantially decreased (8). Coronary artery bypass graft surgerys now more frequently performed with one or more arterial
onduits, but the impact of this change on reduction in
ong-term need for repeat revascularization is less certain.
It is sobering that the MJI experienced a catch-up
henomenon for the CABG cohort relative to the PTCA
roup. Previously, some authors have conjectured that
lacing a bypass graft not only treats the culprit lesion but
he entire vessel proximal to the lesion and, therefore,
rovides better protection. These angiographic data do not
onfirm this hypothesis at five-year follow-up. Actually, it
oints to the possibility that lesion progression may be more
requent after CABG, and this may add to the risk of
schemia when the graft becomes compromised. Again, this
s somewhat concerning because these data were taken at
ve years, a time when the saphenous vein graft failure rates
ave not yet peaked.
It must be recognized that in this entire discussion we
ave used “progression of atherosclerosis” very loosely.
ngiography has been shown to be an inadequate tool to
ccurately assess disease progression. It is possible that
egative remodeling of vessels contributes to smaller lumen
nd that the angiographic changes may not be solely from
laque progression (9). Furthermore, the current data are
olely derived from an angiographic index, and no func-
ional studies were performed to actually measure the
olume of ischemic myocardium to incorporate the signif-
cance of scar, collaterals, or small-vessel disease. Unques-
ionably, the greatest implication of this study is to make
atients and doctors more aware that the revascularization
rocedure is not a cure for atherosclerotic CAD.
Whichever method of revascularization is used, very aggres-
ive risk factor modification should be pursued to prevent the
rogression of atherosclerosis. That the rate of tobacco use was
nchanged from the index to follow-up angiography is dis-
ressing. The increasing use of statins is encouraging, but in
hese highly acclaimed medical centers, the rate of their use in
his study was far from exemplary. It has been repeatedly
hown that optimal treatment of patients with CAD results in
etter outcome (10). All efforts should be geared towards
chieving this “simple” goal. Although these angiographic
ndings from the BARI study present more fodder to debate
hich revascularization strategy is better, we should not repeat
he mistake of getting too close to the trees so as to lose sight
f the forest. The major message from this analysis is that we
hould be very cognizant about the reality of CAD progression
n a relatively short timeframe. We should not overemphasize
he importance of the revascularization procedure choice but
ather shift our focus from the vulnerable plaque to the
ulnerable patient.
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